Leadership
Penny joins us most recently from Vallon Pharmaceuticals, Inc. where she was the SVP of Regulatory Affairs & Program Management for Vallon’s ADAIR (abuse deterrent immediate release dextroamphetamine sulfate) and ADMIR (abuse deterrent immediate release methamphetamine sulfate) programs as well as in-licensing opportunities of other assets for their portfolio. Penny has worked on providing regulatory leadership for the development, approval, and maintenance of several products in various therapeutic areas including Amlexanox, Avandia, Copaxone, Fentora, Fragmin, Gabitrol, Genotropin, Symlin injection, and Tolteradine.
